MELanoma Brain Metastasis Treated With CYberknife

The therapeutic landscape of metastatic melanoma has undergone a radical transformation in the last decade, largely due to the recent introduction of immune checkpoint inhibitors (IT) and targeted therapies (TTs), and advances in surgery and radiotherapy (RT), which have changed the outlook of patients with melanoma brain metastasis.

Radiation therapy has been and remains an important component of treatment for patients with melanoma brain metastases.

Particularly, stereotactic radiosurgery (SRS), highly precise RT technique, for single or a small number of metastases, has emerged as a crucial component in the management of melanoma brain metastases, with whole brain RT usually reserved for selected patients who have widespread intracranial metastatic disease. SRS relies on the delivery of concentrated, high doses of radiation to one or more metastatic brain lesions of otherwise radio-resistant tumors such as melanoma, providing effective local control (LC) of the disease while minimizing damage to surrounding healthy tissue. SRS can be employed both as an independent primary local therapy, allowing a swifter transition to systemic therapy compared to classic surgical resection and as a salvage procedure after ineffective systemic treatment when the number of MBMs remains below 5-10 and their size is below 3 cm.

A recent systematic review of RT alone for MBMs reported a median survival of 7.5 months (IQR-6.7-9.0-months) after SRS and 3.5 months (IQR-2.4-4.0-months) after whole brain RT.

Although these advances have successfully improved the outcomes of patients with metastatic melanoma, its management remains challenging and complex, requiring a multidisciplinary approach that integrates surgery, systemic therapy, and RT to optimize patient outcomes.

Ongoing investigations in this field are now focused on determining the best strategies to combine RT modalities with systemic therapies (IT and TT), emphasizing the potential for synergistic effects that enhance treatment efficacy. However, data on optimal sequencing and toxicity management, particularly in the context of radiosurgery, remain limited and require careful evaluation. The approach of combining RT with IT or TT has therefore become established in practice but this strategy has not been evaluated in randomized controlled trials. Clinical guidelines vary in the strength of their recommendations for combining different treatments. Studies differ in terms of patient selection, the extent of extracranial disease, the number of lesions treated, and the definitions of concurrent versus non-concurrent therapies. These differences make it challenging to draw definitive conclusions about the optimal treatment strategy for melanoma brain metastases.

In this prospective observational study, the investigators aim to analyse the impact of RT in a well selected population of patient receiving SRS at the European Institute of Oncology- IRCCS- Milan- as first local approach for MBMs, in combination with different type and timing of systemic treatment.

By analysing data from patients treated with CyberKnife from 2026 to 2028, the investigatorsseek to provide insights into the effectiveness of SRS according LC, overall survival (OS) and progression-free survival (PFS) in this patient population.

The investigators aim to investigate also potential prognostic factors including demographic, clinical, and therapeutic factors, with a focus on the influence of concurrent versus non-concurrent systemic therapies.

Through this prospective observational study, the investigators aim both to contribute to the growing body of evidence supporting the use of SRS as a viable treatment option for patients with MBMs and to identify factors that may enhance treatment efficacy and improve patient outcomes.

• Overall survival (OS) [Time frame: From the end of radiotherapy through study completion, every three months.]
• Progression-free survival (PFS) [Time frame: From the end of radiotherapy through study completion, every three months.]
• Intracranial out-field progression free survival (IOFPFS) [Time frame: From the end of radiotherapy through study completion, every three months.]
• Overall intracranial progression free survival (OIPFS) [Time frame: From the end of radiotherapy through study completion, every three months.]
• Extracranial progression free survival (EPFS) [Time frame: From the end of radiotherapy through study completion, every three months.]
• Local control (LC) [Time frame: From the end of radiotherapy through study completion, every three months.]
• Adverse events [Time frame: From the end of radiotherapy through study completion, every three months.]
• Quality of Life data (QoL) - EORTC QLQ BN20 [Time frame: From the baseline (start of radiotehrapy), to the end of study (12 months), every three months.]
• Quality of Life data (QoL) - EORTC QLQ C30 questionnaires. [Time frame: From the baseline (start of radiotehrapy), to the end of study (12 months), every three months.]